Tirzepatide vs Ozempic: Which Costs Less in 2026?

TL;DR

• Ozempic runs about $930 to $1,030 per month at retail; tirzepatide (Mounjaro/Zepbound) costs $1,000 to $1,200, but manufacturer self-pay options bring both as low as $199 to $499 per month.
• With commercial insurance and savings cards, both can cost as little as $25 per month for qualifying patients.
• Tirzepatide produced greater weight loss (20 to 23% of body weight) versus semaglutide (about 15%) in head-to-head trials, meaning cost per percentage of weight lost may actually favor tirzepatide.

What Does Ozempic Cost?

Ozempic is made by Novo Nordisk and contains semaglutide. It is FDA-approved for type 2 diabetes and for reducing cardiovascular and kidney disease risk in certain patients. It is not FDA-approved for weight loss on its own, though it is widely prescribed off-label for that purpose.

At full retail price, a month's supply of Ozempic typically costs between $930 and $1,030, depending on dose and pharmacy. Costco and some mail-order pharmacies may come in slightly lower. The list price in U.S. is significantly higher than in other countries. A Peterson-KFF analysis found that same supply costs roughly $169 in Japan and under $100 in several European nations.

For patients with commercial insurance that covers Ozempic, Novo Nordisk savings card can reduce copay substantially. For patients paying out of pocket or without coverage, Novo Nordisk now offers Ozempic through NovoCare at a reduced self-pay price of $199 per month for starting doses and $349 per month for maintenance doses.

Ozempic generally has broader insurance formulary coverage than tirzepatide, partly because it has been on market longer (FDA-approved in 2017). Many insurance plans list it as a preferred GLP-1 option for diabetes, and its additional cardiovascular and kidney indications have strengthened its coverage position.

What Does Tirzepatide Cost?

Tirzepatide is made by Eli Lilly and sold under two brand names: Mounjaro (for type 2 diabetes) and Zepbound (for weight loss and obstructive sleep apnea). Both contain same active ingredient.

Mounjaro costs roughly $900 to $1,050 per month at retail without insurance. Zepbound is slightly higher at about $1,000 to $1,200 per month. The difference between two brands comes down to which indication your doctor prescribes it for and how your insurance categorizes it.

Eli Lilly has introduced lower-cost single-dose vials through their LillyDirect program. These vials, which require drawing medication into a syringe yourself, are available at self-pay prices of $299 per month for 2.5 mg starting dose, $399 for 5 mg, and $499 for higher doses (7.5 mg through 15 mg). This makes tirzepatide more accessible for patients without insurance coverage.

With commercial insurance that covers Mounjaro or Zepbound, Eli Lilly's savings card can bring monthly cost down to as little as $25.

Insurance coverage for tirzepatide is still catching up. Because it is newer, some plans require prior authorization or step therapy (trying Ozempic or another GLP-1 first) before covering tirzepatide. However, more plans are adding it each year, and gap in coverage is narrowing.

Side-by-Side Price Comparison

Here is a simplified view of what you might pay under different circumstances:

Full retail (no insurance, no savings):

• Ozempic: $930 to $1,030 per month
• Mounjaro: $900 to $1,050 per month
• Zepbound: $1,000 to $1,200 per month

Manufacturer self-pay programs:

• Ozempic via NovoCare: $199 to $349 per month
• Tirzepatide vials via LillyDirect: $299 to $499 per month

With commercial insurance + manufacturer savings card:

• Ozempic: As low as $25 per month
• Mounjaro/Zepbound: As low as $25 per month

Medicare and Medicaid:

• Ozempic is more widely covered under Medicare Part D for diabetes. Coverage for weight loss is generally not available under Medicare or Medicaid for either medication, though exceptions may apply for specific comorbidities.

Which Gives You More Value for Money?

This is where comparison gets interesting. If you look strictly at monthly sticker price, Ozempic is a little cheaper. But if you measure cost per outcome, picture changes.

In SURPASS-2 trial, tirzepatide was compared directly against semaglutide in people with type 2 diabetes. The highest tirzepatide dose (15 mg) produced an average weight loss of nearly 25 pounds over 40 weeks, while semaglutide (1 mg) resulted in about 12.5 pounds. For A1C reduction, tirzepatide also outperformed semaglutide at all dose levels tested.

A more recent head-to-head trial published in The New England Journal of Medicine in 2025 compared two at their maximum weight-loss doses. Tirzepatide produced an average weight loss of 20.2% of body weight over 72 weeks, compared to 13.7% for semaglutide. That is a meaningful gap.

One analysis calculated that cost to achieve each 1% reduction in body weight was $985 with tirzepatide versus $1,845 with semaglutide. By that measure, tirzepatide offers more weight loss per dollar spent, even though its monthly price is slightly higher.

Of course, individual results vary. Some people respond better to semaglutide, and others do better on tirzepatide. The best medication for you depends on your specific health goals, tolerance for side effects, and how your body responds.

If you are considering switching between these medications, this resource covers practical details of transitioning: Semaglutide to Tirzepatide Conversion

How Do They Differ Beyond Cost?

Understanding non-cost differences helps explain why one might be worth more to you even if it costs slightly more.

Tirzepatide activates both GLP-1 and GIP receptors. This dual mechanism gives it a broader metabolic effect. It produces greater appetite suppression, stronger blood sugar reduction, and more weight loss on average compared to semaglutide, which activates only GLP-1 receptors.

Ozempic has proven cardiovascular and kidney benefits. The SELECT and FLOW trials demonstrated that semaglutide reduces risk of heart attack, stroke, cardiovascular death, and slows kidney disease progression. These are significant benefits for patients who have heart or kidney concerns alongside diabetes. Tirzepatide does not yet have equivalent FDA-approved cardiovascular or kidney indications, though trials are ongoing.

Side effects are similar for both. Nausea, vomiting, diarrhea, and constipation are most common, especially during dose escalation. Some studies suggest tirzepatide may cause slightly more GI side effects at higher doses, but overall tolerability is comparable.

Ozempic now has an oral tablet form available (as Rybelsus), though this is a separate brand. An oral semaglutide tablet specifically for weight loss (oral Wegovy) was also FDA-approved in late 2025. Tirzepatide does not yet have an oral option, though clinical trials for oral tirzepatide are underway.

For a look at how tirzepatide compares to newer dual-agonist competitors, this guide may be useful: Mazdutide vs Tirzepatide

How to Pay Least for Either Medication

Regardless of which medication you and your provider choose, a few steps can help you minimize your out-of-pocket costs.

Check your insurance formulary first. Your plan may cover one but not other, or may have different copay tiers for each. A quick call to your plan or a look at formulary list online can save you time and money.

Apply for manufacturer savings card before filling your first prescription. Both Eli Lilly and Novo Nordisk offer these programs, and for patients with qualifying commercial insurance, they can reduce monthly cost to $25.

If you are uninsured or your plan does not cover either, go directly to manufacturer self pay programs. NovoCare for Ozempic and LillyDirect for tirzepatide vials both offer substantial discounts over retail pharmacy pricing.

Ask about prior authorization. Many plans require it for GLP-1 medications, especially for weight loss. A well-documented submission from your provider can make difference between a denial and an approval.

Consider total cost of treatment, not just monthly price. If tirzepatide helps you reach your goals faster or produces better results, it may cost less overall even if monthly price is slightly higher. A medication that works better and keeps you on track for a shorter total treatment period can be more economical in long run.

FDA Drug Information Database

Conclusion

Tirzepatide and Ozempic are both effective medications for type 2 diabetes and weight management, but they have meaningful differences in cost, coverage, and clinical performance. At retail, Ozempic is slightly cheaper. But manufacturer self-pay programs have brought both into a similar price range for cash-paying patients. With insurance and savings cards, either can cost as little as $25 per month.

Tirzepatide produces greater weight loss and stronger blood sugar control in head-to-head trials, which may make it better value despite a higher monthly price. Ozempic has advantage of proven cardiovascular and kidney benefits, broader insurance coverage, and an oral option. The right choice depends on your health priorities, your insurance situation, and how your body responds to treatment. Talk to your provider about which medication makes most sense for your specific goals and budget.